Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
The company posted net profit of Rs.34.24 crores for the period ended June 30, 2020.
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
PAT rises to Rs 195.76 crore
The transaction is expected to close in the Q4FY22
Forex gains stood at Rs 20 crore for the quarter
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
He will be stationed at the company HQ in Bengaluru, India
Subscribe To Our Newsletter & Stay Updated
